Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study

• 作者: Wu Yuchen Sun Xuefei Bai Xueyan Qian Jun Zhu Hong Cui Qu Xing Ruixian Chen Yuedan Liu Qing Lai Wenyuan Li Junhong Wang Yaming Sun Shengjun Ji Nan Liu Yuanbo
• 来源期刊: 中华神经外科杂志（英文）
• 关键词: Central nervous system B cell lymphoma SCNSL R-MIADD Chemotherapy
• 年，卷（期）: 2021,（2）
• 所属期刊栏目: Research
• 页码范围: 143-150
• 页数: 8页
• 语种: 中文
• DOI: 10.1186/s41016-021-00238-0

摘要

Background::Secondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined.Methods::We conducted a retrospective study to assess the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients.Results::Nineteen patients with newly diagnosed CNS lesions were selected, with a median age of 58 (range 20 to 72) years. Out of 19 patients, 11 (57.9%) achieved complete remission (CR) and 2 (10.5%) achieved partial remission (PR); the overall response rate was 68.4%. The median progression-free survival after CNS involvement was 28.0 months (95% confidence interval 11.0-44.9), and the median overall survival after CNS involvement was 34.5 months. Treatment-related death occurred in one patient (5.3%).Conclusions::These single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL, further investigation is warranted.